Novartis Investigative Site

Santander 39008

0 studies enrolling now · 7 studies all time

What they study most

Adenocarcinoma, Carcinoma, Chronic Obstructive Pulmonary Disease, Hypernephroid, Melanoma, Neoplasms, Breast, Nephroid Carcinoma, Non-Small Cell Lung Cancer, Pulmonary Arterial Hypertension, Renal Cell, Thrombocytopaenia

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer — Stopped early
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia — Completed
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer — Completed
• Imatinib (QTI571) in Pulmonary Arterial Hypertension — Completed
• A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) — Completed